p16 INK4a and p15 INK4b genes, which encode two functionally related CDK inhibitors, recently emerged as candidate tumor suppressor genes since they were both localized to 9p21, which frequently undergoes hemizygous and homozygous deletion in a variety of tumor types. To determine the mode of inactivation of these two genes in human esophageal squamous cell carcinoma (ESCC), we performed multiple molecular analyses in 60 ESCC specimens from Linxian, China using DNA methylation assay, LOH analysis, deletion screening and SSCP-sequencing. We observed that p16 INK4a inactivation was predominantly associated with aberrant methylation in the CpG island of its promoter region, whereas p15 INK4b frequently had homozygous deletions. Compared with aberrant methylation, which occurred in 17 of 34 cases, homozygous deletion of p16 INK4a and LOH at its nearby D9S942 microsatellite marker were observed at a much lower frequency (17%). Intragenic mutation in p16 INK4a gene was rare. In contrast, homozygous deletion in p15 INK4b and LOH at the nearby D9S171 marker were observed at frequencies of 35 and 47%, respectively, and the two events were significantly associated with each other. On the other hand, aberrant methylation of p15 INK4b was relatively infrequent (6/34) and occurred concomitantly with p16 INK4a methylation. Among the 60 cases, only four contained a continuous homozygous deletion spanning both p15 INK4b and p16 INK4a . Six cases were exclusively deleted at p16 INK4a and 17 exclusively deleted at p15 INK4b . LOH at D9S942 and D9S171 was also found to be mutually exclusive. Our results suggest that the alteration mode at 9p21 was not uniform, and the two genes were inactivated by distinct mechanisms. Altogether, 68% of the samples harbor at least one type of alteration in p16 INK4a gene and 50% of the samples were altered in p15 INK4b gene, indicating that they are the frequent inactivating targets during ESCC development.
Introduction
The putative tumor suppressor genes p16(INK4a/MTS1/ CDKN2) and p15(INK4b/MTS2) encode two important cyclin dependent kinase (CDK) inhibitors which negatively regulate G 1 -S transition of the proliferating cells by contributing to the maintenance of pRb in an active (hypophosphorylated) state Abbreviations: CDK, cyclin-dependent kinase; ESCC, esophageal squamous cell carcinoma; LOH, loss of heterozygosity; SSCP, single strand conformation polymorphism; MI, microsatellite instability.
(1,2). p16 INK4a binds to and inhibits CDK4/6 activity during G 1 stage (3). p15 INK4b binds to the cyclin D-dependent kinase and prevents p27 association. p27 then binds to, and inactivates, cyclin E-CDK2 complex, thereby blocking the cell cycle at the G 1 -S boundary (4) . The absence of the inhibitory effect of p16 INK4a or p15 INK4b on the cyclin/CDK enzymes predisposes the cells to a risk of uncontrolled cell growth.
Inactivation of p16 INK4a and p15 INK4b genes has been observed in many types of human cancers including esophageal squamous cell carcinoma (ESCC). Multiple mechanisms seem to be involved in causing gene inactivation (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Some studies showed that germline mutations in p16 INK4a gene might be related to familial melanoma (6) , but in general the mutation is relatively infrequent in sporadic melanoma and most other cancers (7) . Allelic loss, observed as loss of heterozygosity (LOH) at 9p21 is common in various cancer types and is often an early event (8, 9) . Homozygous deletions of p16 INK4a and p15 INK4b also occur at significant frequencies and sometimes correlate with a high risk of metastasis (10, 11) . Hemizygous and homozygous deletion at 9p21 are widely considered to be one of the primary mechanisms of p16 INK4a /p15 INK4b inactivation and may play an important role in the invasiveness of many cancers during their late stage. It was hypothesized that, due to the existence of multiple tumor suppressor genes including p16 INK4a , p15 INK4b and p19 ARF (which is translated from an alternatively spliced product of p16 INK4a gene using a different open reading frame) (12) in this region, deletion of a large piece of genomic material would be more effective over point mutation to eliminate two or more critical genes (13) . Recently, aberrant methylation of the CpG island at the promoter regions of p16 INK4a and p15 INK4b genes was reported in many cancers (14) and was associated with loss of transcription (15, 16) . Interestingly, it was observed that for most epithelialderived tumors, inactivation via promoter methylation occurs exclusively for p16 INK4a , whereas in most hematopoietic malignancies and gliomas, this mechanism seems to involve the p15 INK4b gene only (17, 18) . This suggests that promoter hypermethylation could be involved in the selective inactivation of targets at 9p21 region in different types of tumor.
In human ESCC, the functional significance of p16 INK4a alteration is still unclear. Although p16 INK4a gene has been shown to be deleted, mutated or hypermethylated in a number of ESCC cell lines, molecular analysis from primary tumors has not consistently indicated the alterations of this gene in vivo (19) (20) (21) (22) (23) (24) . For example, frequencies of homozygous deletion in cell lines range from 33 to 92% (19) , whereas in primary tumors, only 0-16% have been observed (20, 21) . This apparent discrepancy could be due to (i) p16 INK4a deletion as a result of in vitro immortalization or selection during culturing; (ii) loss of p16 INK4a during very late stages of ESCC progression or (iii) technical difficulties in detecting homozygous deletion from primary tumor DNA due to contamination of DNA from normal tissue. The frequency of p16 INK4a mutations in primary tumors also vary among reports, from 0 to 50%, and differed INK4b genes in the tumor samples. Matched pairs of normal and tumor DNA samples were screened for homozygous deletion using multiplex-PCR, and for frequency of LOH at 9p21 using two microsatellite markers D9S942 and D9S171. Among these samples, 34 were further analysed by PCR-methylation assay to evaluate aberrant methylation at the gene promoter regions and by SSCP-sequencing to examine p16 INK4a mutation.
Materials and methods
Tumor samples and DNA preparation Sixty surgically-resected esophageal specimens containing both tumor and nearby normal tissues were collected between 1991 and 1993 from patients with primary ESCC in Linxian (now Linzhou City), Henan Province, China, and were fixed in 80% ethanol. Approximately 20 mg of normal tissue from each sample was used directly for DNA extraction. All tumor tissues were embedded in paraffin, cut into 5 µm serial sections and deparaffinized before use. H&E staining and histopathological examination were performed on representative sections from each sample block to determine the tumor region. Tumor tissues were dissected from the neighboring four successive sections. Generally, contamination of the normal cells was~20-25% mainly due to the fibroblast and inflammatory cells surrounding the cancer nests which were difficult to remove. Genomic DNA was extracted by proteinase K digestion and phenol-chloroform extraction.
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PCR amplification
Primer sequences for all PCR amplifications in this study are shown in Table  I . Sets 1 (GDB:188218) and 4 (GDB:370738) were obtained from the GDB database through internet, and were used for LOH assay. Sets 2 and 5 (21) were used in the PCR-methylation assay. Set 3 was used for p15 INK4b gene deletion analysis. Sets 6 and 7 were used in deletion assay and single strand conformation polymorphism (SSCP)-sequencing of p16 INK4a gene. All primers not given the source were designed using a primer picking software developed by Whitehead Institute/MIT Center for Genome Research. For PCR reaction, genomic DNA was amplified in a total volume of 25 µl containing 20 pmol of each primer, 250 µmol of dNTP, 1.4-2.0 mM MgCl 2 , standard buffer and 0.5 U Taq polymerase (all from Gibco BRL). Mg 2ϩ concentration, PCR cycles and annealing temperature (T m ) were optimized for each assay in pilot experiments.
PCR-based gene deletion and LOH analysis
Homozygous deletion at the p16 INK4a and p15 INK4b loci was analysed by comparative multiplex PCR using the D9S171 product or β-actin fragment as internal standards, and a closely sized PCR fragment of the gene as the primary target. The D9S171 microsatellite marker was originally selected to access LOH at 9p21. It was also used as an internal control in addition to β-actin because it was never found to be homozygously deleted and is relatively close to the target genes on the same chromosome. This provides a similar exposure rate of both the target and the control to the Taq polymerase, and can also identify LOH at D9S171 simultaneously. However, p15 INK4b deletion was only analysed with the β-actin internal control, because the p15 INK4b exon 2 has a size overlap with the D9S171 product.
To ensure linear amplification, PCR cycle number for tumor and normal DNA reactions were experimentally determined based on the product intensity versus cycle number gradient curve using a modified protocol originally described by Gonzales-Zulueta et al. (16) . For PCR amplification, about 200 ng normal and 60 ng tumor genomic DNA were used. Forward primers of both target gene and control were radiolabeled at the 5Ј end with [γ-33 P]dATP. Typically, the following PCR conditions were used: 5 min denaturation at 95°C before adding the Taq polymerase; 2 min at 95°C, 2 min at T m , 2 min at 72°C for initial cycle; then 27-29 cycles of 90 s at 95°C, 45 s at T m , 45 s at 72°C; followed by 2 min at 72°C. The PCR products were resolved on 6 or 20% polyacrylamide gel depending on product size difference. After autoradiography for 4 h, the film was developed and the ratio of intensity of the target gene versus control was measured and calculated using a computer imaging system (Image-Pro Plus, Media Cybernetics). A homozygous deletion was scored if the normalized signal intensity (target/β-actin) in the tumor lane was Ͻ25% of that in the normal lane. The threshold was so chosen because of the possible 20-25% non-cancerous cell contamination in our tumor samples. LOH at D9S171 was determined simultaneously with p16 INK4a deletion, whereas LOH at D9S942 was determined separately.
PCR-based methylation assay
Normal DNA (400 ng) and tumor DNA (80 ng) were digested for 4 h with 10 U methylation-sensitive (CfoI, HpaII, SmaI) or methylation-insensitive (MspI) restriction enzymes. After 2 min incubation at 95°C to inactivate the enzymes, the DNAs were subject to a second round of digestion by another 10 U freshly added enzymes to improve specificity and completeness of 
a ϩ , intact gene; -, homozygous deletion; ϩ/-, heterozygous deletion (LOH); M, methylation; MI, microsatellite instability; Mut, mutation; NI, noninformative. b Cases not analysed for methylation due to insufficient amount of DNA.
digestion (all of the enzymes are from Gibco BRL and digestion was performed under manufacturer's instructions). Since p16 INK4a and p15 INK4b promoter regions have common methylation-sensitive restriction sites (i.e. HpaII), the same digested DNA samples were used to determine methylation status of both genes. One hundred nanograms of normal and 20 ng of tumor DNA were amplified by PCR using primer set 2 or 5 which flanks the restriction sites, and with β-actin as internal control. The PCR conditions were similar to those described in the deletion assay with cycle number fine-tuned to limit the amplification to a linear range. PCR products were electrophoresed on 3% agarose gels. Same amounts of undigested and MspI-digested DNA were used as the controls in every sample examined. Experiments were repeated three times for all samples to ensure reproducibility Signal intensities normalized by the internal control were measured and calculated as described in the deletion analysis. Methylation at a specific restriction site was determined by the ratio of the normalized intensity (target/internal standard) of the samples pretreated with methylation-sensitive enzymes over that of the undigested samples. A ratio Ͼ0.5 was defined as aberrant methylation.
Single strand conformation polymorphism (SSCP) and sequencing analysis
PCR was carried out as described with 1 µCi of α-32 P-dATP. The labeled PCR products were denatured and electrophoresed on 6% polyacrylamide gel containing glycerol at 10-25 W for 7-10 h. Shifted bands from the tumor DNA reaction as compared with the adjacent normal sample, as well as the human placental control were eluted and amplified by a second PCR followed by agarose gel electrophoresis. The final PCR products were purified for DNA sequencing using the Wizard PCR Preps DNA Purification System from Promega (Madison, WI) according to manufacturer's instructions. DNA sequencing was performed using the same primer for PCR-SSCP. DNA was sequenced with the Thermal Sequenase Cycle Sequencing Kit from Amersham Life Science (Cleveland, OH) according to the manufacturer's instructions. In cycle sequencing, the thermal cycle consisted of 2 min at 94°C; 20 cycles of 1 min at 94°C, 1 min at 58°C and 1 min at 72°C; 10 cycles of 1 min at 94°C and 1 min at 72°C; and 1 min at 72°C. The reaction mixture was loaded on a 6% polyacrylamide sequencing gel made from the Sequagel DNA Sequencing Solutions (National Diagnostics, Atlanta, GA).
Results
LOH at 9p21 loci in primary ESCC
Genomic DNA obtained from 60 matched pairs of primary tumors and nearby normal tissues were examined for incidence of LOH at 9p21 where both p16 INK4a and p15 INK4b reside. Altogether, 17 of the 51 informative cases were found to harbor LOH at least one of the two loci we analysed (Table  II) . However, frequency of LOH at individual locus was significantly different. Allelic loss at D9S942 (Figure 1a) , which is located close to p16 INK4a in a region up to 35kb long between p16 INK4a and p15 INK4b , was evident in eight of the 47 informative cases. Whereas nine out of the 19 informative cases showed allelic imbalance at D9S171 (Figure 1b) , which is~2-3 Mb centromeric to the p15 INK4b gene. No case was found to contain LOH at both loci. In all 60 pairs of tumor and normal DNA samples, retention of at least one allele of the D9S171 microsatellite marker was observed. However, there were six cases showing no PCR product for the similar sized D9S942 marker after several attempts. This implies a possible homozygous deletion at the D9S942 locus. Microsatellite instability (MI) at these two loci was also monitored in the same analysis. Only two cases were found to harbor MI in marker D9S942. Interestingly, in one case, variation of the number of nucleotide repeats was seen in both alleles (Figure 1a) . locus. The deletion was evidenced by the loss of the exon 2 PCR product while retaining the D9S171 product in a multiplex PCR reaction (Figure 2a) , and was confirmed by parallel PCR reactions targeting exon 1 with β-actin as control. A significantly higher frequency of homozygous deletion at the p15 INK4b locus, however, was observed in the same sample collection, with 21 out of 60 devoid of exon 2 product ( Figure  2b ). Among these 21 cases, 17 contained deletion only at p15 INK4b loci and four had dual deletions at both p16 INK4a and p15 INK4b loci. All of the four cases with dual deletions at both loci were among the six cases that failed to produce the D9S942 product during the LOH study, implying a large and contiguous deletion encompassing the p16 INK4a -p15 INK4b region in these samples. For the remaining two cases with no D9S942 amplification, one was found to have a deletion at p16 INK4a , the other had a p15 INK4b deletion. Altogether, 27 out of the 60 primary ESCC patients contain homozygous deletion at the 9p21 region, with p15 INK4b being the most frequently targeted gene. The remaining 33 samples had no homozygous deletion in either of the genes (Table II) . Relationship between the p16 INK4a and p15 INK4b homozygous deletion and 9p21 LOH was studied (Table III) . There was no significant association between LOH at D9S942 and homozygous deletion of the p16 INK4a gene (P ϭ 0.488). The incidence of D9S942 LOH, however, was significantly higher in samples with no p15 INK4b deletion (P ϭ 0.023). Nevertheless, LOH at D9S171 is strongly associated with homozygous deletion at p15 INK4b (P ϭ 0.017), but not with that at p16 INK4a . INK4a and p15 INK4b promoter region Among the 60 cases of ESCC we analysed, 34 had yielded enough genomic DNA for us to examine the methylation status of the p16 INK4a and p15 INK4b promoter regions depicted in Figure 3a . Aberrant methylation of p16 INK4a in the tumor DNA was detected in 17 of the 34 cases (Figure 3b ). Among them, 13 were found to be hypermethylated as manifested by their resistance to all three methylation-sensitive restriction enzymes while being sensitive to the methylation-insensitive enzyme MspI. The remaining four cases contained partial methylation as shown by their sensitivity to less than three of the methylationsensitive enzymes, a phenomena indicating that methylation in these cases did not cover the entire CpG island and, therefore, exposing some of the sites to enzymatic restriction. Among these four cases, two cases showed abnormal methylation pattern in which the targeted regions were resistant to MspI restriction, but sensitive to one of the methylationsensitive enzymes. This suggests the existence of an unconventional methylation pattern such as m CCGG, rather than the standard C m CGG pattern in these patients, which would confer their resistance to MspI digestion. Out of the 17 methylated cases of ESCC, 14 cases did not have methylation in the normal DNA. In the remaining three cases, partial methylation, which covered a subset of the sites methylated in the tumors was seen in normal DNA (data not shown). There were 17 cases (50%) in which no PCR product was obtained from the genomic DNA after treatment with any one of the methylationsensitive enzymes. Among them, four samples did not produce PCR products even when not treated with the enzymes, and they all corresponded to the p16 INK4a homozygous deletion cases found in the deletion analysis. The other 13 cases could undergo PCR normally when no restriction enzymes were applied and, therefore, were believed to contain no methylation at p16 INK4a promoter region.
Aberrant methylation of the CpG island in p16
A much lower frequency of aberrant methylation in the p15 INK4b promotor region was observed by analysing the same digested DNA samples used in p16 INK4a methylation assay with amplifiers specific for p15 INK4b promoter region. This region contains 2 HpaII/MspI sites and is 171 bp upstream exon 1. Only six samples out of 34 harbored aberrant methylation (Figure 3c ), all of them also contained aberrant methylation in the p16 INK4a promoter. Among the 28 cases where no PCR product was obtained from the HpaII or MspI treated genomic DNA, 11 actually correspond to the cases previously detected with a homozygous deletion at p15 INK4b locus. The remaining 17 samples were determined as having no aberrant methylation of p15 INK4b promotor. 
Intragenic mutation of p16 INK4a gene in ESCC
PCR products of exons 1 and 2 of p16 INK4a gene from the same 34 pairs of primary ESCC and normal tissues were analysed by SSCP. Except for four cases, which showed homozygous deletion at p16 INK4a locus, all others had specific PCR products. Only one mobility shift was detected in exon 1 of the 31 tumor samples, whereas all of the other normal and tumor DNAs showed normal SSCP pattern (Figure 4a ). Upon sequencing, the exon 1 shifted band was determined to contain a microdeletion of 18 nucleotides starting at codon 20 ( Figure 4b ). This in frame microdeletion will result in a truncated form of p16 INK4a protein. Sequencing analysis of all the other cases showed normal p16 INK4a sequence.
Discussion
In this study, a detailed analysis of the inactivation patterns of two related genes, p16 INK4a and p15 INK4b , was conducted in primary human ESCC. As summarized in Figure 5 , preferential aberrant methylation of the p16 INK4a promoter and homozygous deletion of p15 INK4b gene were found to be frequent events in primary ESCC, along with some other less frequent aberrations.
Previously, we have observed frequent absence of p16 INK4a immuno-reactivity in ESCC samples (22) . In the present study, among the 28 cases in which we were able to analyse different types of p16 INK4a aberration status, 19 harbored at least one type of molecular alteration within the gene or in its vicinity that potentially inactivates the gene (Table IV) . In those samples that had been previously examined for p16 INK4a immunohistochemistry (22) , their p16 INK4a staining patterns generally agree with the p16 INK4a gene status. These results suggest that p16 INK4a is a frequent inactivating target comparable with p53 in ESCC (25) . However, unlike p53, mutation in p16 INK4a gene is rare in our cases. Although we could not exclude the possibility that some mutations may remain undetected by our SSCP method, our observation is consistent with the recent report that p16 INK4a mutation is in general infrequent in ESCC (19) . Among several inactivation modes, aberrant methylation, which can result in transcriptional silencing of the targeted gene, was the most frequent alteration found in p16 INK4a locus. Our frequency of aberrant methylation (50%) is significantly higher than that (19%) reported by Maesawa et al. (21) for a group of Japanese ESCC patients, but is consistent with the observation by Merlo et al. (15) in several other epithelium-derived cancers. To ensure data reliability, efforts were made to avoid incomplete digestion and false amplification using strict quality control procedures including double digestion, linear stage PCR and independent repeats. All results were based on semi-quantitative measurements. In most cases we studied (14/17), aberrant methylation of p16 INK4a was only observed in the tumor, but not in the normal tissues, which implied a transcription-silencing state of the gene only in tumor cells. However, in three cases, a less severe aberrant methylation was also detected in the 'normal' samples dissected from regions close to the tumors. Whether this is due to aberrant methylation in the p16 INK4a promoter region of the preneoplastic cells needs further investigation. It has been reported for colon cancer that promoter methylation can be a very early event which precedes many genetic abnormalities such as p53 and Ras mutations (26) . Recently, Wong et al. (27) also observed aberrant methylation in early lesions of esophageal adenocarcinoma. It is possible that in ESCC, promoter methylation also plays an important role in p16 INK4a inactivation during the early carcinogenic process.
The moderate frequency (17%) of homozygous deletion of the p16 INK4a gene in comparison with the frequent aberrant methylation, suggested that deletion is not a major cause of p16 INK4a inactivation in ESCC. Previous studies showed that p16 INK4a homozygous deletions were predominantly observed in ESCC cell line and metastatic lesions (20, 21) , which imply deletion as a late event involved in the acquisition of invasiveness. We observed that LOH at D9S942, an indication of allelic imbalance of the nearby p16 INK4a gene, had the same frequency to that of the p16 INK4a homozygous deletion, INK4a was not methylated or deleted ( Figure 5 ). This suggests that p16 INK4a is the primary target of aberrant methylation on 9p, and p15 INK4b is also methylated in some cases during this process. On the other hand, homozygous deletion was more frequently involved in p15 INK4b inactivation. Observed in 21 out of the 60 ESCC samples, our frequency is higher than many previous reports (13, 29, 30) . The frequent p15 INK4b inactivation in this study may be related to the special patient population, which was from Linxian, China, a region with high incidence of ESCC. Except for four cases, all the p15 INK4b homozygous deletions were observed without a concomitant p16 INK4a deletion, which contrasts previous findings in many cell line studies (20) . In studies of ESCC cell lines, Tanaka et al. (20) (20, 21) , which are close to our observation and are significantly lower than the frequency in cell line.
In our study, different frequencies of LOH were observed at D9S942 and D9S171, and no cases harbored LOH at both loci, suggesting a non-uniform alteration mode on 9p21. The LOH frequency at the 9p21 region centromeric to p15 INK4b (D9S171) is 47%, much higher than that of D9S942 in the region between p16 INK4a and p15 INK4b (17%), and has a statistically significant association with deletion at p15 INK4b (P ϭ 0.017). LOH on chromosome 9p region has been suggested as an early alteration in cancers such as head and neck SCC and esophageal adenocarcinoma (8, 9, 31) . It is possible that the non-uniformity of LOH at 9p21 may also have originated during the early stage of ESCC development in our samples. The p15 INK4b gene may be lost through an early, followed by a late, deletion of one copy each of the gene. Since the D9S171 locus where frequent LOH was observed is~2 Mb upstream p15 INK4b , we cannot exclude the possibility of the existence of additional critical gene(s) in the vicinity of p15 INK4b , such as p19 ARF (12, 32) , being co-targeted. The frequent p15 INK4b alteration (Table IV) suggests that it is an important factor involved in ESCC development. The importance of p15 INK4b inactivation in the neoplastic transformation may be directly linked to its role in controlling proliferation in normal cells. p15 INK4b can displace p27 from the cyclin D-CDK4 complex, thereby promoting p27 binding and inactivation of cyclin E-CDK2 (5). This non-constitutive CDK/CDI/pRb pathway can be induced by TGF-β and plays an essential role of growth inhibition in normal cells (33) . An early loss of p15 INK4b may cause the cell to be insensitive to the growth inhibition signal.
The observation that different mechanisms are involved in the inactivation of closely located genes like p16 INK4a 
